Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides.

Mutations have been identified in the beta2-microglobulin gene of tumor cells of two metastatic melanoma patients who received immunizations with MAGE peptides. One mutation abolishes the start codon whereas the other introduces a premature stop codon. The second beta2-microglobulin allele of both tumors appears to be lost on the basis of sequence data and loss of microsatellite heterozygosity. The lack of beta2-microglobulin gene product results in the absence of HLA class I antigens on the surface of the tumor cells. This may explain why the tumors of both patients progressed despite the immunization treatment and shows the necessity of analyzing in depth the antigen presentation capability of the tumor cells for the interpretation of clinical trials involving anti-tumor vaccination.

[1]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[2]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[3]  S. Steinberg,et al.  Heterogeneous expression of melanoma‐associated antigens and HLA‐A2 in metastatic melanoma in vivo , 1998, International journal of cancer.

[4]  P. Bruggen,et al.  T cell defined tumor antigens , 1997 .

[5]  F. Oesch,et al.  Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.

[6]  P. Stern,et al.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.

[7]  F. Garrido,et al.  High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. , 1996, Tissue antigens.

[8]  J. Bodmer,et al.  Mechanisms of loss of HLA class I expression on colorectal tumor cells. , 1996, Tissue antigens.

[9]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[10]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[11]  F. Gudat,et al.  Identification and intracellular location of MAGE-3 gene product. , 1995, Cancer research.

[12]  Cécile Fizames,et al.  The 1993–94 Généthon human genetic linkage map , 1994, Nature Genetics.

[13]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[14]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[15]  M. Maio,et al.  Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. , 1991, The Journal of clinical investigation.

[16]  P. Fisher,et al.  Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. , 1990, Cancer research.

[17]  J. Minna,et al.  Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Garrido,et al.  HLA class I antigens in human tumors. , 1995, Advances in cancer research.

[19]  S. Ferrone,et al.  Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.

[20]  M. R. Oliva,et al.  Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas. , 1988, Experimental and clinical immunogenetics.